Mr. Mark Quick reports

CONAVI MEDICAL CORP. ANNOUNCES CLOSING OF $10M PUBLIC OFFERING

Conavi Medical Corp. has closed its previously announced equity offering for aggregate gross proceeds of $10-million.

"This financing provides Conavi with the capital to execute the next important phase of our U.S. commercialization strategy," said Thomas Looby, chief executive officer of Conavi. "With our FDA-cleared hybrid IVUS-OCT imaging system, our focus is now on placing systems in U.S. hospitals, supporting initial clinical adoption and building the foundation for broader commercialization. We are grateful for the strong support of our new and existing investors and their confidence in Conavi as we advance this next stage of our growth."

The company intends to use the net proceeds from the offering to complete a limited market release in the United States of the company's Novasight Hybrid system. The company also intends to use the net proceeds for working capital and other general corporate purposes.

Bloom Burton Securities Inc. acted on behalf of a syndicate of agents in connection with the offering. Under the offering, subscribers either purchased common shares at 20 cents per common share or prefinanced common share purchase warrants for 19.999 cents per prefinanced common share purchase warrant. Investors purchased a total of 50,000,775 securities (consisting of 34,500,775 common shares and 15.5 million prefinanced warrants) for gross proceeds of $10-million. Each prefinanced warrant issued in lieu of a common share at the election of a subscriber entitles the holder thereof to acquire one common share at an exercise price of 0.001 cent per common share. The prefinanced warrants will not expire.

In Canada, the securities purchased pursuant to the offering were qualified for sale by way of a short form prospectus dated July 29, 2026, which was filed in British Columbia, Alberta and Ontario. The securities were also purchased by way of private placement in the United States, pursuant to exemptions from the registration requirements under the U.S. Securities Act of 1933 and pursuant to all applicable U.S. state securities laws. In addition, the securities were also sold by way of private placement in certain other jurisdictions outside of Canada and the United States pursuant to and in compliance with applicable securities laws.

The agents received a total cash commission of $450,864.11 and 2,254,365 compensation options of the company. Each compensation option entitles the holder to buy one common share at a price of 20 cents per common share until expiry on Aug. 12, 2028.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration.

We seek Safe Harbor.